Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
Wenting Wu(East China Normal University), M. D. Prados(Mayo Clinic), Kathleen R. Lamborn(University of California, San Francisco), Judith R. OʼFallon(University of California, San Francisco), P. J. Novotny(Neurological Surgery), Shannon Chang(Mayo Clinic in Florida), K. A. Jaeckle(Mayo Clinic), Jan C. Buckner(McGill University)
Cited by 102
Related Papers
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
|Journal of Clinical Oncology|2006|725
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol
|International Journal of Radiation Oncology*Biology*Physics|2004|564